Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

Clinical trial NCT00085904 · COMPLETED

Trial details

NCT number: NCT00085904
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Cancer Lymphoma

Start date: 2004-04-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.